β痕迹蛋白与心血管疾病的研究进展

陈云宪; 唐良秋

doi:10.13201/j.issn.1001-1439.2014.12.003

β痕迹蛋白与心血管疾病的研究进展

陈云宪,
唐良秋^,

- 粤北人民医院心内科(广东韶关, 512026)

详细信息

通讯作者: 唐良秋,E-mail:tlq_550488@sina.com

中图分类号: R54

收稿日期: 2014-03-06

β-trace protein and cardiovascular disease

CHEN Yunxian,
TANG Liangqiu^,

- Department of Cardiology, Yuebei People's Hospital, Shaoguan, Guangdong, 512026, China

More Information

Corresponding author: TANG Liangqiu, E-mail: tlq_550488@sina.com

Received Date: 06 March 2014

摘要

摘要: β痕迹蛋白(β-trace protein,BTP)亦称为lipocalin型前列腺素D合酶(1ipocalin-type prostagladin D synthase,L-PGDS),是一种糖基化、双功能单体蛋白质,具有催化前列腺素D2(PGD2)的合成和转运亲脂性物质的作用。近年研究显示,BTP具有抗炎症、抗血栓形成、抗细胞凋亡、抗动脉粥样硬化等心血管保护作用,可作为多个心血管疾病的良好标志物。本文就BTP在心血管疾病中的最新研究进展作一综述。
- β痕迹蛋白 /
- lipocalin型前列腺素D合酶 /
- 心血管疾病
Abstract: β-trace protein, known as lipocalin type prostaglandin D synthase, is a N-glycosylated dual functional monomeric protein, and acts as a PGD2 producing enzyme and also as a lipophilic ligand-binding protein. More recently, BTP was found to have cardiovascular protection, such as antiatherogenic,antithrombogenic, antiapoptotic, and antiinflammatory effects, and acts as good predictor to several cardiovascular disease.This article reviews the advanced research of BTP in cardiovascular disease.
- β-trace protein /
- lipocalin type prostaglandin D synthase /
- cardiovascular disease

HTML全文

参考文献(46)

[1]	URADE Y.Structure and function of prostaglandin D synthase[J].Tanpakushitsu Kakusan Koso, 2008, 53:217-226.
[2]	ORENES-PINERO E, MANZANO-FERNANDEZ S, LOPEZ-CUENCA A, et al.beta-Trace protein:from GFR marker to cardiovascular risk predictor[J].Clin J Am Soc Nephrol, 2013, 8:873-881.
[3]	陈小华,谷俊朝.L-PGDS与中枢神经系统疾病[J].中国病原生物学杂志, 2013, 8(3):278-280.
[4]	NAGATA N, FUJIMORI K, OKAZAKI I, et al.De novo synthesis, uptake and proteolytic processing of lipocalin-type prostaglandin D synthase, beta-trace, in the kidneys[J].FEBS J, 2009, 276:7146-7158.
[5]	MATSUOKA T, HIRATA M, TANAKA H, et al.Prostaglandin D2 as a mediator of allergic asthma[J].Science, 2000, 287:2013-2017.
[6]	EGUCHI Y, EGUCHI N, ODA H, et al.Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients[J].Proc Natl Acad Sci U S A, 1997, 94:14689-14694.
[7]	LOPEZ-CUENCA A, MANZANO-FERNANDEZ S, MARIN F, et al.Beta-trace protein and cystatin c as predictors of major bleeding in non-ST-segment elevation acute coronary syndrome[J].Circ J, 2013, 77:2088-2096.
[8]	INOUE T, EGUCHI Y, MATSUMOTO T, et al.Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease[J].Atherosclerosis, 2008, 201:385-391.
[9]	MANZANO-FERNANDEZ S, LOPEZ-CUENCA A, JANUZZI J L, et al.Usefulness of beta-trace protein and cystatin C for the prediction of mortality in non ST segment elevation acute coronary syndromes[J].Am J Cardiol, 2012, 110:1240-1248.
[10]	KANAOKA Y, AGO H, INAGAKI E, et al.Cloning and crystal structure of hematopoietic prostaglandin D synthase[J].Cell, 1997, 90:1085-1095.
[11]	TABA Y, SASAGURI T, MIYAGI M, et al.Fluid shear stress induces lipocalin-type prostaglandin D (2) synthase expression in vascular endothelial cells[J].Circ Res, 2000, 86:967-973.
[12]	NEGORO H, SOO S W, HAKAMADA-TAGUCHI R, et al.Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1following interleukin stimulation in bovine endothelial cells[J].J Hypertens, 2002, 20:1347-1354.
[13]	TANAKA R, MIWA Y, MOU K, et al.Knockout of the l-pgds gene aggravates obesity and atherosclerosis in mice[J].Biochem Biophys Res Commun, 2009, 378:851-856.
[14]	CHEUNG C L, CHEUNG T T, LAM K S, et al.Reduced serum beta-trace protein is associated with metabolic syndrome[J].Atherosclerosis, 2013, 227:404-407.
[15]	FUJIMORI K, ARITAKE K, URADE Y.A novel pathway to enhance adipocyte differentiation of 3T3-L1 cells by up-regulation of lipocalin-type prostaglandin D synthase mediated by liver X receptor-activated sterol regulatory element-binding protein-1c[J].J Biol Chem, 2007, 282:18458-18466.
[16]	FUJITANI Y, ARITAKE K, KANAOKA Y, et al.Pronounced adipogenesis and increased insulin sensitivity caused by overproduction of prostaglandin D2 in vivo[J].FEBS J, 2010, 277:1410-1419.
[17]	CIPOLLONE F.The balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans[J].Arterioscler Thromb Vasc Biol, 2004, 24:1259-1265.
[18]	李文龙,李新华,刘恒方,等.兔动脉粥样硬化组织mPGES-1、L-PGDS的表达及辛伐他汀预处理对其表达的影响[J].实用医学杂志, 2012, 28(8):1251-1253.
[19]	MIWA Y, TAKIUCHI S, KAMIDE K, et al.Identification of gene polymorphism in lipocalin-type prostaglandin D synthase and its association with carotid atherosclerosis in Japanese hypertensive patients[J].Biochem Biophys Res Commun, 2004, 322:428-433.
[20]	CHRISTODOULIDIS G, VITTORIO T J, FUDIM M, et al.Inflammation in coronary artery disease[J].Cardiol Rev, 2014.
[21]	ZHOU Y, SHAW N, LI Y, et al.Structure-function analysis of human l-prostaglandin D synthase bound with fatty acid molecules[J].FASEB J, 2010, 24:4668-4677.
[22]	TABA Y, MIYAGI M, MIWA Y, et al.15-deoxydelta 12, 14-prostaglandin J2 and laminar fluid shear stress stabilize c-IAP1 in vascular endothelial cells[J].Am J Physiol Heart Circ Physiol, 2003, 285:H38-H46.
[23]	NEGORO H, SHIN W S, HAKAMADA-TAGUCHI R, et al.Endogenous prostaglandin D (2) synthesis decreases vascular cell adhesion molecule-1expression in human umbilical vein endothelial cells[J].Life Sci, 2005, 78:22-29.
[24]	ALHOUAYEK M, MASQUELIER J, CANI P D, et al.Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6[J].Proc Natl Acad Sci U S A, 2013, 110:17558-17563.
[25]	RICOTE M, LI A C, WILLSON T M, et al.The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation[J].Nature, 1998, 391:79-82.
[26]	ROSSI A, KAPAHI P, NATOLI G, et al.Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase[J].Nature, 2000, 403:103-108.
[27]	卢瑛,李军,李瑛.不同年龄健康人血β痕迹蛋白与肾小球滤过率以及颈动脉内中膜厚度的相关性探讨[J].医学临床研究, 2010, 27(2):235-238.
[28]	INOUE T, TAKAYANAGI K, MOROOKA S, et al.Serum prostaglandin D synthase level after coronary angioplasty may predict occurrence of restenosis[J].Thromb Haemost, 2001, 85:165-170.
[29]	MATSUMOTO T, EGUCHI Y, ODA H, et al.Lipocalin-type prostaglandin D synthase is associated with coronary vasospasm and vasomotor reactivity in response to acetylcholine[J].Circ J, 2011, 75:897-904.
[30]	ANDO J, YAMAMOTO K.Vascular mechanobiology:endothelial cell responses to fluid shear stress[J].Circ J, 2009, 73:1983-1992.
[31]	TOKUDOME S, SANO M, SHINMURA K, et al.Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis[J].J Clin Invest, 2009, 119:1477-1488.
[32]	HOSBOND S E, DIEDERICHSEN A C, PEDERSEN L, et al.Lipocalin-type prostaglandin D synthase is not a biomarker of atherosclerotic manifestations[J].Scand J Clin Lab Invest, 2014, 74:219-227.
[33]	HAN F, TAKEDA K, ISHIKAWA K, et al.Induction of lipocalin-type prostaglandin D synthase in mouse heart under hypoxemia[J].Biochem Biophys Res Commun, 2009, 385:449-453.
[34]	CHIHARA Y, CHIN K, ARITAKE K, et al.A urine biomarker for severe obstructive sleep apnoea patients:lipocalin-type prostaglandin D synthase[J].Eur Respir J, 2013, 42:1563-1574.
[35]	GARVEY J F, TAYLOR C T, MCNICHOLAS W T.Cardiovascular disease in obstructive sleep apnoea syndrome:the role of intermittent hypoxia and inflammation[J].Eur Respir J, 2009, 33:1195-1205.
[36]	MANZANO-FERNANDEZ S, JANUZZI J J, BORONAT-GARCIA M, et al.beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure[J].J Am Coll Cardiol, 2011, 57:849-858.
[37]	KONG P, CHRISTIA P, FRANGOGIANNIS N G.The pathogenesis of cardiac fibrosis[J].Cell Mol Life Sci, 2014, 71:549-574.
[38]	NAGALLA K T, GOLE M, CLAUDINO M A, et al.Alteration in myocardial prostaglandin D synthase expression in pressure overload-induced left ventricular remodeling in rats[J].Exp Biol Med (Maywood), 2012, 237:24-30.
[39]	FRUNGIERI M B, WEIDINGER S, MEINEKE V, et al.Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma:Possible relevance to human fibrotic disorders[J].Proc Natl Acad Sci U S A, 2002, 99:15072-15077.
[40]	BRAUNWALD E.Heart Failure[J].JACC Heart Fail, 2013, 1:1-20.
[41]	ASTOR B C, SHAFI T, HOOGEVEEN R C, et al.Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population[J].Am J Kidney Dis, 2012, 59:653-662.
[42]	RAGOLIA L, PALAIA T, PARIC E, et al.Prostaglandin D2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells[J].J Biol Chem, 2003, 278:22175-22181.
[43]	HIRAWA N, UEHARA Y, YAMAKADO M, et al.Lipocalin-type prostaglandin d synthase in essential hypertension[J].Hypertension, 2002, 39:449-454.
[44]	BHAVSAR N A, APPEL L J, KUSEK J W, et al.Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD[J].Am J Kidney Dis, 2011, 58:886-893.
[45]	UEHARA Y.PGD (2)/L-PGDS system in hypertension and renal injury[J].Nihon Yakurigaku Zasshi, 2004, 123:23-33.
[46]	ITO H, YAN X, NAGATA N, et al.PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis[J].J Am Soc Nephrol, 2012, 23:1797-1809.